PP Amarin Related News
NICE recommends VAZKEPA® (icosapent ethyl) to reduce cardiovascular risk
Icosapent ethyl has been recommended by NICE for use across the NHS in England and Wales to reduce cardiovascular (CV) risk in adult statin-treated...
Tackling cardiovascular disease in Europe
Laurent Abuaf, SVP and President Europe at Amarin, outlines the social and economic burden of CVD in Europe and the company’s key priorities for...
Amarin: Changing the landscape of residual cardiovascular disease risk
World-leading pioneers of the pharmaceutical industry, Amarin Corporation, comprehensively explore the ever-evolving landscape of cardiovascular disease, analysing the current challenges facing mitigating the impacts...
